Citius Oncology, Inc.

NASDAQ:CTOR

Drug Manufacturers - General

Healthcare
$0.56 +4.23%

+$0.03 today

Market cap
$51.83M
Beta
3.42
P/E (TTM)
-1.6
EPS (TTM)
-$0.42
52W Low $0.49High $6.19

Volume 0.15M

Average 0.12M

CTOR Income Before Tax

Profit after all operating and non-operating items but before income tax.

Citius Oncology, Inc.NASDAQ: CTOR

Income Before Tax · Q2 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q2 FY2026 income before tax was -$26.84M, compared with -$7.47M a year earlier. Trailing-twelve-month income before tax was -$41.95M.

Context

  • Income before tax grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$26.84M or moves back toward the trailing-twelve-month quarterly average of -$10.49M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$26.84M-409.3% QoQ
Last fiscal yearSep 2025
-$23.7M-15.2% YoY
LTMMar 2026
-$41.95M-66.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-259.3%——
1 year-15.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(23.7M) USD
Year-over-year change
-15.2%

Income Before Tax vs competitors

How CTOR compares with its peers on the latest reported figures

  • CTOR's LTM Mar 2026 income before tax of -$41.95M is the 4th highest of the 10 companies compared; the peer median is -$46.9M.
  • Its year-over-year change of -66.7% is the 6th highest of 10, against a peer median of +14.9%.
  • Income before tax amounts to 747.6% of revenue for CTOR, versus a peer median of 606.7%.
CTOR Competitors Peer median
Income Before Tax for CTOR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LNSRLENSAR, Inc.LTM Mar 2026$29.4M +151.9%—50.9%
SPROSpero Therapeutics, Inc.LTM Mar 2026$15.5M +122.2%—28.3%
ACTUActuate Therapeutics IncLTM Mar 2026-$21.54M +14.9%——
CTORCitius Oncology, Inc.LTM Mar 2026-$41.95M -66.7%—747.6%
OWLTOwlet, Inc.LTM Mar 2026-$46.02M -278.7%—43.0%
MCRBSeres Therapeutics, Inc.LTM Mar 2026-$46.9M +22.1%—4088.8%
FBRXForte Biosciences, Inc.LTM Mar 2026-$74.45M -70.3%——
FATEFate Therapeutics, Inc.LTM Mar 2026-$129.91M +26.1%—2056.8%
SCLXScilex Holding CompanyLTM Mar 2026-$393.6M -428.2%—1162.4%
VORVor Biopharma Inc.LTM Mar 2026-$883.08M -644.6%——
Peer median (excluding CTOR) -$46.9M+14.9%—606.7%

Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue0000
Cost of Revenue0000
Gross Profit0000
Gross Margin————
Research & Development6.86M4.24M4.93M6.42M
Selling, General & Admin2.86M7.88M15.65M17.1M
Operating Expenses9.71M12.12M20.57M23.52M
Depreciation & Amortization9.71M000
EBITDA0(12.12M)(20.57M)(23.49M)
EBITDA Margin————
Operating Income(9.71M)(12.12M)(20.57M)(23.52M)
Operating Margin————
Interest Income00036.37K
Interest Expense000218.03K
Other Income / Expenses000(181.66K)
Income Before Tax(9.71M)(12.12M)(20.57M)(23.7M)
Pre-Tax Margin————
Income Tax Expense1.15M576K576K1.06M
Net Income(10.87M)(12.7M)(21.15M)(24.76M)
Net Margin————
EPS (Basic)(0.08)(0.19)(0.30)(0.34)
EPS (Diluted)(0.08)(0.19)(0.30)(0.34)
Weighted Avg Shares90.16M89.48M71.55M73.27M
Weighted Avg Shares (Diluted)90.16M89.48M71.55M73.27M

Citius Oncology, Inc.

NASDAQ:CTOR

Intrinsic Alpha fair value

Locked

Current Price

$0.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.